Evotec SE (EVO) Common Equity (2009 - 2026)
Evotec SE (EVO) reported Common Equity of $819077.1 for Q1 2026, down 14.63% on a YoY basis from $959466.9 in Q1 2025, and down 13.53% sequentially from $947186.9 in Q4 2025.
Evotec SE (EVO) Common Equity (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 10 years of Common Equity data on file, last reported at $819077.1 in Q1 2026.
- For the quarter ending Q1 2026, Common Equity fell 14.63% year-over-year to $819077.1; the trailing twelve-month figure through Mar 2026 stood at $819077.1 (down 14.63% YoY), and the FY2025 full-year result was $947186.9, down 99.91% from the prior year.
- Common Equity slipped to $819077.1 in Q1 2026, from $947186.9 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.2 billion in Q4 2022 to a low of $819077.1 in Q1 2026.
- A 5-year average of $312.9 million and a median of $1.1 million in 2024 frame the typical range for Common Equity.
- Across the five-year window, Common Equity rose 5.81% in 2022 and sank 99.91% in 2025, its largest moves.
- Tracing EVO's Common Equity over 5 years: stood at $1.2 billion in 2022, then dropped by 0.52% to $1.2 billion in 2023, then declined by 15.53% to $1.0 billion in 2024, then slumped by 99.91% to $947186.9 in 2025, then retreated by 13.53% to $819077.1 in 2026.
- Business Quant data shows EVO's Common Equity at $819077.1 in Q1 2026, $947186.9 in Q4 2025, and $935403.1 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 819,077.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 819,077.07 |
| Dec 31, 2025 | 947,186.86 |
| Sep 30, 2025 | 935,403.06 |
| Jun 30, 2025 | 957,396.79 |
| Mar 31, 2025 | 959,466.92 |
| Dec 31, 2024 | 1.02 Bn |
| Sep 30, 2024 | 1.06 Mn |
| Dec 31, 2023 | 1.20 Bn |
| Dec 31, 2022 | 1.21 Bn |
| Sep 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 1.58 Bn |
| Sep 30, 2021 | 1.17 Mn |
| Dec 31, 2020 | 863.76 Mn |
| Dec 31, 2019 | 529.77 Mn |
| Sep 30, 2010 | 171,154.31 |
| Jun 30, 2010 | 152,062.62 |
| Mar 31, 2010 | 156.76 |
| Dec 31, 2009 | 164,636.67 |